B-MoGen’s Lab personnel have extensive expertise in genome engineering. Our primary focus is to help medical researchers and scientists find solutions to their research faster and more accurately, and in turn, help more people live healthier, happier lives.
We are fiercely curious, innovative genome engineers who want to transform genetics research and provide new tools to help bring the cures of the future here today.
Travis Cordie, M.S.
Travis Cordie, M.S. joined the team in 2016, bringing with him his knowledge of bio manufacturing, genetic engineering, pluripotent stem cells and tissue engineering. Graduating from UW-Madison with an M.S. in Biomedical Engineering, Travis studied reprogramming human pluripotent stem cells and tissue engineering. Post graduate school, Travis worked at a Biomanufacturing facility gaining valuable cGMP experience and developing cellular therapies for phase 1 and 2 clinical trials.
Neil Michael Otto, Ph.D.
Lead Scientist, Technical Operations
Neil Michael Otto, Ph.D. started his journey in science as an undergraduate working in the lab of Dr. Michelle Sanders at the University of Minnesota where he studied transcriptional regulator ZEB-1. During his graduate studies at the University of Minnesota, he focused on the protein-protein interactions of autophagy machinery. While under the direction of Dr. Do-Hyung Kim, Neil was able to mature his knowledge of biological research techniques that have been pivotal to this day. He learned and implemented his knowledge of protein biochemistry to investigate the binding conditions of autophagy proteins. He also learned to use TALENs and Crisper/Cas systems to create several autophagy gene knockout lines. During his three years of postdoctoral work under the direction of Lincoln Potter, Neil gained more knowledge in the field of biochemistry and molecular biology. He learned to preform sequence alignments for the identification of key residues in salt bridge formation, and identification of conserved phosphorylation sites important for GC-A catalytic activity. At B-MoGen Biotechnologies, Neil provides a leadership role in advancing B-MoGen’s R&D initiatives through effective planning, organizing, documenting, and active resource allocation to each authorized B-MoGen R&D effort.
David Hermanson, Ph.D.
Lead Scientist, Technical Operations
Dr. Hermanson has spent the last seven years engineering cells with transposon systems to express chimeric antigen receptors (CARs). He received his Ph.D. in medicinal chemistry and performed postdoctoral training at the University of Minnesota. His postdoctoral fellowship with Drs. Melissa Geller and Dan Kaufman focused on the development of novel CARs for natural killer cells derived from induced pluripotent stem cells. From there he began working for Poseida Therapeutics using the piggyBac transposon system to help develop P-BCMA-101, a CAR T cell therapy in clinical trials for multiple myeloma. His primary responsibility was in process development optimizing gene delivery, cell expansion, and developing a cGMP manufacturing process for clinical trials. He is excited to be back in his home state bringing his expertise to B-MoGen in CARs, gene editing, and process development.
Paige joined B-MoGen in 2016 with a Masters of Biomedical Science from the University of Hull and a background working in clinical histopathology laboratories at the National Health Service in the UK. She has previous experience as a production and project manager in addition to supervising product manufacturing at a cosmetic company. She brings her excellent time management skills, managerial experience and a track record of meeting company operations goals to her position as Operations Manager.
Quality Assurance Manager
Anita joined B-MoGen in 2018 as the Quality Assurance Manager. She brings with her 8 years of experience in laboratory management and implementing quality systems including companies in the gene editing space. Anita has a Bachelor’s of Science Degree in Cell/Cellular and Molecular Biology from the University of Minnesota.